A major component in the hepatic synthesis of very low-density lipoprotein (VLDL) and hence LDL, is the transcription and translation of apolipoprotein B-100
(apo B100), the carrier protein of LDL.
No reports describing the use of mipomersen (Kynamro), an oligonucleotide inhibitor of apolipoprotein B-100
synthesis, in human pregnancy have been located.
Data from an analysis of the study participants' atherogenic protein levels demonstrated that subjects experienced statistically significant reductions in lipoprotein(a) Lp(a) and apolipoprotein B-100
Total cholesterol, HDL-c, TG, Apolipoprotein A-1 (Apo A-1), Apolipoprotein B-100
(Apo B-100) and glucose were measured in serum by standardized enzymatic automated methods in a PENTRA-400 autoanalyzer (ABX-Horiba Diagnostics, Montpellier, France).
The complete cDNA and amino acid sequence of human apolipoprotein B-100
The Kynamro injection is an oligonucleotide inhibitor of apolipoprotein B-100
synthesis and has been approved in the US for use in patients with homozygous familial hypercholesterolemia, a genetic disease characterised by extreme cholesterol levels.
Kynamro is an oligonucleotide inhibitor of apolipoprotein B-100
Serum apolipoprotein B-100
concentrations in healthy and diseased cattle.
VLDL is assembled on apolipoprotein B-100
(apoB100) and comprises 50% TG, 20% cholesterol esters, 15% phospholipids and 15% protein.
Lp (a) is an LDL-like particle having an apolipoprotein (a) which is attached to apolipoprotein B-100
by a disulfide linkage.
gene Xba I polymorphism and cholesterol gallstone disease.
In this paper, we first review LDL, apolipoprotein B-100
, the unique protein of LDL, and its oxidation sensitive components.